Buffett Dumps $982 Million in BofA Stock—What Does He Know?

Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.

Get your FREE, no-obligation Wealth Protection Guide now

Scott Pancoast Biography and Net Worth

Director of DermTech

Mr. Scott Pancoast is the Director of DermTech.

What is Scott R. Pancoast's net worth?: The estimated net worth of Scott R. Pancoast is at least $0.00 as of December 14th, 2020. Mr. Pancoast owns 44,132 shares of DermTech stock worth more than $0 as of November 23rd. This net worth estimate does not reflect any other investments that Mr. Pancoast may own. Learn More about Scott R. Pancoast's net worth.
How do I contact Scott R. Pancoast?: The corporate mailing address for Mr. Pancoast and other DermTech executives is 11099 N. Torrey Pines Road Suite 100, La Jolla CA, 92037. DermTech can also be reached via phone at (858) 450-4222 and via email at [email protected]. Learn More on Scott R. Pancoast's contact information.
Has Scott R. Pancoast been buying or selling shares of DermTech?: Scott R. Pancoast has not been actively trading shares of DermTech during the last ninety days. Most recently, Scott R. Pancoast sold 5,000 shares of the business's stock in a transaction on Wednesday, June 30th. The shares were sold at an average price of $42.41, for a transaction totalling $212,050.00. Learn More on Scott R. Pancoast's trading history.
Who are DermTech's active insiders?: DermTech's insider roster includes John Dobak (CEO), Claudia Ibarra (COO), Scott Pancoast (Director), Enrico Picozza (Director), Kevin Sun (CFO), and Todd Wood (Insider). Learn More on DermTech's active insiders.
Are insiders buying or selling shares of DermTech?: In the last year, insiders at the sold shares 5 times. They sold a total of 13,436 shares worth more than $20,494.84. The most recent insider tranaction occured on December, 11th when CFO Kevin M Sun sold 447 shares worth more than $648.15. Insiders at DermTech own 5.1% of the company. Learn More about insider trades at DermTech.
Information on this page was last updated on 12/11/2023.

Scott R. Pancoast Insider Trading History at DermTech

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/30/2021	Sell	5,000	$42.41	$212,050.00
12/14/2020	Sell	6,000	$13.93	$83,580.00	44,132
12/7/2020	Sell	2,382	$12.00	$28,584.00	50,132

Scott R. Pancoast Buying and Selling Activity at DermTech

DermTech Company Overview

DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.

Today's Range

Now: N/A

50 Day Range

MA: $0.19

$0.05

$0.42

2 Week Range

Now: N/A

Volume

3,662,300 shs

Average Volume

1,065,175 shs

Market Capitalization

$3.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.48

JD Vance Predicts: Wall Street vs. Trump & Your Money

From Priority Gold | Ad

Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.

Get your free guide NOW before it's too late.